Related Experiment Video
Updated: Feb 6, 2026
07:51
Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
1.1K
Idiopathic pulmonary artery aneursym.
The Indian Journal of Chest Diseases & Allied Sciences
|June 17, 2014
Summary
Idiopathic pulmonary artery aneurysm (PAA) is a rare condition. This case report details a patient diagnosed with PAA presenting with chest pain, exertional breathlessness, and pedal edema.
Area of Science:
- Cardiology
- Pulmonology
- Vascular Medicine
Background:
- Idiopathic pulmonary artery aneurysm (PAA) is an exceptionally rare vascular lesion.
- Clinical data on PAA is scarce, primarily relying on autopsy findings.
- Understanding the clinical presentation and diagnosis of PAA is crucial due to its rarity.
Observation:
- A patient presented with characteristic symptoms including chest pain, exertional dyspnea, and pedal edema.
- Diagnostic workup confirmed the presence of a pulmonary artery aneurysm.
- The clinical course highlights the importance of considering PAA in patients with relevant symptoms.
Findings:
- The patient was diagnosed with idiopathic pulmonary artery aneurysm.
- The case illustrates a symptomatic presentation of this rare condition.
- Diagnostic imaging confirmed the anatomical abnormality.
Implications:
- This case contributes to the limited clinical experience with idiopathic pulmonary artery aneurysm.
- It underscores the need for heightened clinical suspicion for PAA in symptomatic individuals.
- Further case reports may enhance the understanding of PAA's clinical spectrum and management.
Related Concept Videos
01:30Aneurysm I: Introduction
431
An aortic aneurysm is a localized outpouching or dilation at a weak point in the artery wall. It may involve different parts of the aorta, such as the abdominal aorta, aortic arch, or thoracic aorta.Etiological factorsSeveral disorders are associated with aortic aneurysms.Congenital causes, such as primary connective tissue disorders like Marfan syndrome, impact the integrity and strength of connective tissues, notably affecting the aorta. Marfan syndrome is a genetic disorder that specifically...
431
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
615
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
615
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
477
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
477
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
512
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
512
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
628
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
628
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
550
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
550